PHARMACIA & UPJOHN XALATAN RISK OF IRIDIAL PIGMENTATION TO BE ASSESSED IN FOUR POST-MARKETING STUDIES; APPROVAL RECOMMENDED BY FDA ADVISORY COMMITTEE
Pharmacia & Upjohn will assess the risk of iridial pigmentation associated with administration of its glaucoma therapy Xalatan (latanoprost) in four post-marketing studies, the company reported during a Dec. 9 review of the topical prostaglandin by FDA's Ophthalmic Drugs Subcommittee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth